Calavo Deal Holds Promise, But Execution Risk and Rich Valuation Keep Mission Produce a Wait

What happened

A Zacks article highlights the Calavo acquisition as adding packing capacity, prepared foods, and $25 million in cost synergies, positioning Mission Produce for long-term profitable growth. However, our DeepValue master report underscores significant integration and regulatory risks, including potential antitrust divestitures and the challenge of replicating Calavo's recent operational missteps. The market already appears to price in deal success, with shares trading at 8.3x EBITDA and 25x earnings amid a crowded “global avocado leader” narrative. Absent concrete merger progress or a pullback, the risk-reward remains unfavorably skewed. Investors should await clearer regulatory signals or a price closer to $11, where the margin of safety would better reflect the uncertainties.

Implication

If the Calavo merger closes and delivers targeted synergies, Mission could achieve 9% EBITDA margins and a rerating toward $18; however, failure or delays could push shares to $10, so waiting for a better entry or proof of execution is prudent.

Thesis delta

No change. The master report already incorporates the Calavo deal’s potential and its risks. The Zacks piece adds no new facts or disclosures, so our WAIT rating and $11 attractive entry remain in place, contingent on regulatory clearance and synergy realization.